Aleksander L Sieroń

Prof. Aleksander L Sieroń

Department of Molecular Biology, Slaski Uniwersytet Medyczny w Katowicach, 40-055 Katowice, Poland
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1999 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
ACAlain Colige
Alain Colige
Aleksander L SierońAleksander L Sieroń
Aleksander L Sieroń
SLShi-Wu Li
Shi-Wu Li
USUlrike Schwarze
Ulrike Schwarze
EPElizabeth Petty
Elizabeth Petty
BNBetty V. Nusgens
Betty V. Nusgens

20 July 2021 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
AFAgnieszka Fus-Kujawa
Agnieszka Fus-Kujawa
PPPawel Prus
Pawel Prus
KBKarolina Bajdak-Rusinek
Karolina Bajdak-Rusinek
PTPaulina Teper
Paulina Teper
KGKatarzyna Gawron
Katarzyna Gawron
Aleksander L SierońAleksander L Sieroń
Aleksander L Sieroń
Transfection is a powerful analytical tool enabling studies of gene products and functions in eukaryotic cells. Successful delivery of genetic material into cells depends on DNA quantity and quality, incubation time and ratio of transfection reagent to DNA, the origin, type and the passage of transfected cells, and the presence or absence of serum in the cell culture. So far a number of transfection methods that use viruses, non-viral particles or physical factors as the nucleic acids carriers have been developed. Among non-viral carriers, the cationic polymers are proposed as the most attractive ones due to the possibility of their chemical structure modification, low toxicity and immunogenicity. In this review the delivery systems as well as physical, biological and chemical methods used for eukaryotic cells transfection are described and discussed.

14 May 1996 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SLS W Li
S W Li
Aleksander L SierońAleksander L Sieroń
Aleksander L Sieroń
AFA Fertala
A Fertala
YHY Hojima
Y Hojima
WAW V Arnold
W V Arnold
DPD J Prockop
D J Prockop
Bone morphogenic protein-1 (BMP-1) was originally identified as one of several BMPs that induced new bone formation when implanted into ectopic sites in rodents. BMP-1, however, differed from other BMPs in that it its structure was not similar to transforming growth factor beta. Instead, it had a large domain homologous to a metalloendopeptidase isolated from crayfish, an epidermal growth-factor-like domain, and three regions of internal sequence homology referred to as CUB domains. Therefore, BMP-1 was a member of the "astacin families" of zinc-requiring endopeptidases. Many astacins have been shown to play critical roles in embryonic hatching, dorsal/ventral patterning, and early developmental decisions. Here, we have obtained amino acid sequences and isolated cDNA clones for procollagen C-proteinase (EC 3.4.24.19), an enzyme that is essential for the processing of procollagens to fibrillar collagens. The results demonstrate that procollagen C-proteinase is identical to BMP-1.


18 March 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ACAlain Colige
Alain Colige
SLShi-Wu Li
Shi-Wu Li
Aleksander L SierońAleksander L Sieroń
Aleksander L Sieroń
BNBetty V. Nusgens
Betty V. Nusgens
DPDarwin J. Prockop
Darwin J. Prockop
CLCharles M. Lapière
Charles M. Lapière
Procollagen N-proteinase (EC3.4.24.14) cleaves the amino-propeptides in the processing of type I and type II procollagens to collagens. Deficiencies of the enzyme cause dermatosparaxis in cattle and sheep, and they cause type VIIC Ehlers–Danlos syndrome in humans, heritable disorders characterized by accumulation of pNcollagen and severe skin fragility. Amino acid sequences for the N-proteinase were used to obtain cDNAs from bovine skin. Three overlapping cDNAs had an ORF coding for a protein of 1205 residues. Mammalian cells stably transfected with a complete cDNA secreted an active recombinant enzyme that specifically cleaved type I procollagen. The protein contained zinc-binding sequences of the clan MB of metallopeptidases that includes procollagen C-proteinase/BMP-1. The protein also contained four repeats that are homologous to domains found in thrombospondins and in properdin and that can participate in complex intermolecular interactions such as activation of latent forms of transforming growth factor β or the binding to sulfatides. Therefore, the enzyme may play a role in development that is independent of its role in collagen biosynthesis. This hypothesis was supported by the observation that in some tissues the levels of mRNA for the enzyme are disproportionately high relative to the apparent rate of collagen biosynthesis.

10 October 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
MBMalwina Botor
Malwina Botor
Agnieszka Fus-KujawaAgnieszka Fus-Kujawa
Agnieszka Fus-Kujawa
MUMarta Lucyna Uroczynska
Marta Lucyna Uroczynska
KSKarolina Stepien
Karolina Stepien
AGAnna Galicka
Anna Galicka
Aleksander L SierońAleksander L Sieroń
Aleksander L Sieroń
Osteogenesis Imperfecta (OI) is a group of connective tissue disorders with a broad range of phenotypes characterized primarily by bone fragility. The prevalence of OI ranges from about 1:15,000 to 1:20,000 births. Five types of the disease are commonly distinguished, ranging from a mild (type I) to a lethal one (type II). Types III and IV are severe forms allowing survival after the neonatal period, while type V is characterized by a mild to moderate phenotype with calcification of interosseous membranes. In most cases, there is a reduction in the production of normal type I collagen (col I) or the synthesis of abnormal collagen as a result of mutations in col I genes. Moreover, mutations in genes involved in col I synthesis and processing as well as in osteoblast differentiation have been reported. The currently available treatments try to prevent fractures, control symptoms and increase bone mass. Commonly used medications in OI treatment are bisphosphonates, Denosumab, synthetic parathyroid hormone and growth hormone for children therapy. The main disadvantages of these therapies are their relatively weak effectiveness, lack of effects in some patients or cytotoxic side effects. Experimental approaches, particularly those based on stem cell transplantation and genetic engineering, seem to be promising to improve the therapeutic effects of OI.